Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS).

Journal of clinical immunology - 1 Oct 2015

Yokoyama Seiji, Perera Pin-Yu, Terawaki Seigo, Watanabe Nobumasa, Kaminuma Osamu, Waldmann Thomas A, Hiroi Takachika, Perera Liyanage P

Abstract excerpt

PURPOSE: Autoimmune lymphoproliferative syndrome (ALPS) is a non-malignant genetic disorder of lymphocyte homeostasis with defective Fas-mediated apoptosis. Current therapies for ALPS primarily target autoimmune manifestations with non-specific immune suppressants with variable success thus highlighting the need for better therapeutics for this disorder. METHODS: The spectrum of clinical manifestations of ALPS is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoimmune Lymphoproliferative Syndrome
Share to fas Receptor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoglobulins

Share to Janus Kinase 3

Share to Mice, Inbred MRL lpr

Share to Piperidines

Share to Pyrroles

Share to T-Lymphocytes, Regulatory

Source

Open in PubMed Open full text

Identifiers

PMID: 26453583
DOI: 10.1007/s10875-015-0203-z
PMCID: PMC7780245

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS).PMID 26453583Read ↗

Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS).Semantic proximity Read ↗

New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndromeSemantic proximity Read ↗

Autoimmune lymphoproliferative syndrome: A disorder of immune dysregulation.Semantic proximity Read ↗

Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype.Semantic proximity Read ↗

Autoimmune Lymphoproliferative Syndrome (ALPS)Semantic proximity Read ↗

A genetic disorder of lymphocyte apoptosis involving the fas pathway: the autoimmune lymphoproliferative syndrome.Semantic proximity Read ↗

Advances in autoimmune lymphoproliferative syndromes.Semantic proximity Read ↗

ALPS, FAS, and beyond: from inborn errors of immunity to acquired immunodeficiencies.Semantic proximity Read ↗

The Autoimmune Lymphoproliferative Syndrome with Defective FAS or FAS-Ligand Functions.Semantic proximity Read ↗

Immunologic evaluation and genetic defects of apoptosis in patients with autoimmune lymphoproliferative syndrome (ALPS).Semantic proximity Read ↗

IL-10/Janus kinase/signal transducer and activator of transcription 3 signaling dysregulates Bim expression in autoimmune lymphoproliferative syndrome.Semantic proximity Read ↗

The expanding spectrum of the autoimmune lymphoproliferative syndromes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.